Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Proportion of multidrug-resistant tuberculosis among rifampicin-resistant cases evaluated using the GeneXpert MTB/RIF assay in Western China: A retrospective observational study.

Created on 30 Oct 2026

Authors

Zhenzhen Zhao, Yanjun Si, Mengjiao Li, Dan Huang, Huiyu Zhong, Tangyuheng Liu, Hao Chen, Yi Zhou, Binwu Ying

Published in

The Journal of international medical research. Volume 54. Issue 10. Pages 3000605261500319. Epub Oct 30, 2026.

Abstract

ObjectiveDrug-resistant tuberculosis (TB), particularly multidrug-resistant TB (MDR-TB),tuberculosis, remains a significant public health problem in Western China. This study aimed to evaluate the prevalence of rifampicin and isoniazid resistance, including multidrug-resistant tuberculosis, and to assess the proportion of multidrug-resistant tuberculosis cases among those with rifampicin resistance as detected using GeneXpert MTB/RIF assay, with multidrug-resistant tuberculosis defined based on the MeltPro TB assay.MethodsThis retrospective observational study employed a cross-sectional diagnostic concordance design. In total, 345 patients were enrolled between December 2022 and September 2023; among these, 280 (81.16%) were newly diagnosed. Drug susceptibility profiles were determined using the MeltPro TB and GeneXpert MTB/RIF assays. Multidrug-resistant tuberculosis was defined based on the MeltPro TB assay, which served as the molecular reference rather than a definitive gold standard. Sensitivity and positive predictive value were calculated with 95% confidence intervals against MeltPro-defined multidrug-resistant tuberculosis.ResultsAmong the 345 patients, 22 (6.38%) were isoniazid-monoresistant, 12 (3.48%) were rifampicin-monoresistant, and 33 (9.57%) had multidrug-resistant tuberculosis. Among the 209 samples positive on both MeltPro and GeneXpert MTB/RIF, 30 (14.35%) were rifampicin-resistant according to the GeneXpert MTB/RIF; 25 (83.33%) of these had MeltPro-defined multidrug-resistant tuberculosis. This proportion differed according to treatment history, with 11/16 (68.75%) among newly diagnosed patients versus 14/14 (100.00%) among previously treated patients. The sensitivity of GeneXpert MTB/RIF detected rifampicin resistance against MeltPro-defined multidrug-resistant tuberculosis among newly diagnosed patients was 100.00% (95% confidence interval, 71.51-100.00), and the positive predictive value was 68.75% (95% confidence interval, 44.03-87.07).ConclusionsOnly 68.75% of newly diagnosed patients with GeneXpert MTB/RIF detected rifampicin resistance had multidrug-resistant tuberculosis, indicating that rifampicin resistance is a suboptimal surrogate for multidrug-resistant tuberculosis in this population. These estimates are concordance-based rather than accuracy against a definitive reference standard, and comprehensive testing for both isoniazid and rifampicin susceptibility should be performed in clinical practice to guide treatment and mitigate transmission.

PMID:
42958930
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement